Information Provided By:
Fly News Breaks for May 16, 2017
IONS, ALNY
May 16, 2017 | 08:09 EDT
Leerink analyst Paul Matteis expects yesterday's data from Ionis Pharmaceuticals (IONS) will put TTRrx at a commercial disadvantage to Alnylam's (ALNY) patisiran. The top-line results for TTRrx, which showed high efficacy and several safety issues, is the best case for Alnylam, Matteis tells investors in a research note. He raised his odds of approval for both programs but lowered his price target for Ionis to $45 from $47. Matteis has Market Perform ratings on both stocks.
News For ALNY;IONS From the Last 2 Days
There are no results for your query ALNY;IONS